India’s role as the "Pharmacy of the World" is closely tied to its robust bulk drug (API) manufacturing sector. With the Government of India’s focus on API self-reliance through schemes like the PLI and Bulk Drug Parks, the landscape is rapidly evolving. However, to truly achieve global leadership, there’s a need to address key areas like process innovation, supply chain resilience, quality standards, sustainability, and regulatory harmonization.
The Pharma Bulk Drug Manufacturing Summit 2025 aims to bring together top industry leaders, technocrats, regulatory authorities, and innovators to share insights, explore challenges, and unlock new opportunities for sustainable and globally competitive API manufacturing.









Dr. Appaji Padmanabhuni
Founder & Former Director General of Pharmexcil India, Former Director at NPPA, Government of India, and Former Officer, Drugs Control Department, Government of Andhra Pradesh/Telangana

Shri. Ch. A.P. Rameswara Rao
National President, BDMAI
Bulk Drug Manufacturers of India

Vice president & Head of Quality
Centaur Pharmaceuticals Pvt. Ltd.

Senior General Manager, Corporate Quality Assurance, Themis Medicare Limited

President – Operations, Site Head-Manufacturing Excellence.
ICHOR BIOLOGICS PVT. LTD

Vice President & Head Drug Product Manufacturing, Biological E Limited, Hyderabad

President & Chief Technology Officer
Jodas Expoim Pvt. Ltd.

Head, API-Research & Development
Shilpa Pharma Ltd

Chief Technology Officer - Biotechnology,
Biophore India Pharmaceuticals Pvt. Ltd

President & CTO
SCL Lifesciences Ltd.
Formerly Saurav chemicals Ltd

General Manager SCM
Chemveda Lifescience Pvt Ltd

Head of Regulatory Affairs
Neuland Laboratories

Vice-President (Operations)
Srikem Laboratories Private Limited

Vice President- API R&D, Apitoria Pharma (A 100% subsidiary of Aurobindo Pharma Ltd.)

Head Quality API,
Piramal Pharma Ltd

Senior Vice President - Quality, NATCO Pharma

Chief Procurement Officer,
Neuland Laboratories Limited

Head of Supply Chain Management

RAC, Founder and Managing Director, Masuu Global Solutions

Co-Founder And CEO, Awarathon

GM - Marketing & Operations, Polmon Instruments Pvt Ltd

Head of CQA,
Neuland Laboratories Limited









Ø Driving Self-Reliance in API Manufacturing: Policy, Potential & Progress
Ø Reducing dependence on Chinese imports
Ø Bulk Drug Parks & PLI Scheme: Updates & Opportunities
Ø Infrastructure & logistics as enablers
Ø Flow chemistry, enzymatic synthesis
Ø Continuous vs batch processing
Ø Energy and cost efficiencies
Ø Tackling USFDA/EDQM audit challenges
Ø Building data integrity and QA culture
Ø Role of digitization in regulatory compliance
Ø Continuous Manufacturing vs. Batch: What’s the Future?
Ø Adopting Process Intensification and PAT (Process Analytical Technology)
Ø Cost Optimization Without Compromising Quality
Ø Green Chemistry Practices in Bulk Drug Manufacturing
Ø Effluent Treatment & Zero Liquid Discharge: Regulatory Outlook
Ø How ESG is Impacting CDMO Partnerships and Licensing
Ø Meeting USFDA, EU-GMP, and WHO-GMP Requirements
Ø Addressing Regulatory Gaps in Exporting APIs
Ø Audit Readiness for Global Markets
Ø Digital Twins, IoT, and Automation for Plant Optimization
Ø Equipment Innovation for Scale and Energy Efficiency
Ø Smart Plant Equipment & Digital Solutions for APIs
Ø Global positioning & export competitiveness
Ø Technology partnerships & talent building
Ø Integrating ESG goals into manufacturing
BlueTech Media LLP
Office no - 203, 2nd floor, Aditya Heritage, besides Rustomjee Elanza, Malad west, 400064
Copyright © 2025 BlueTech Media LLP - All Rights Reserved.
Designed by Whyte Wings Media